RenovoRx (RNXT) Expected to Announce Quarterly Earnings on Monday

RenovoRx (NASDAQ:RNXT) is expected to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $0.42 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, April 1, 2026 at 9:30 AM ET.

RenovoRx Trading Down 1.0%

Shares of NASDAQ:RNXT opened at $1.00 on Monday. The firm has a 50 day moving average of $0.94 and a 200-day moving average of $1.01. The stock has a market capitalization of $36.65 million, a PE ratio of -2.78 and a beta of 1.34. RenovoRx has a 12 month low of $0.70 and a 12 month high of $1.45.

Institutional Investors Weigh In On RenovoRx

Hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd increased its position in RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock worth $42,000 after purchasing an additional 18,525 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of RenovoRx during the second quarter worth $98,000. Citadel Advisors LLC bought a new stake in shares of RenovoRx during the third quarter worth $154,000. Wealthspire Advisors LLC acquired a new position in shares of RenovoRx during the fourth quarter worth $212,000. Finally, Geode Capital Management LLC lifted its stake in shares of RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after acquiring an additional 31,730 shares during the last quarter. 3.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of RenovoRx in a research report on Monday, December 29th. Wall Street Zen upgraded RenovoRx from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. JonesTrading raised RenovoRx to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Ascendiant Capital Markets lifted their price target on RenovoRx from $12.50 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.00.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.